PA
ABVX

Pinnacle Associates’s Abivax ABVX Stock Holding History

Pinnacle Associates’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208K Buy
+1,864
New +$221K ﹤0.01% 903

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Pinnacle Associates's ABVX Position: Q1 2026 in Review

Pinnacle Associates opened a new position in Abivax (ABVX) in Q1 2026: 1,864 shares worth $208K. The stake represents ﹤0.01% of the portfolio and ranks #903 among its holdings.

254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Pinnacle Associates held 1,864 shares of Abivax worth $208K as of Q1 2026.
  • Abivax was a new Pinnacle Associates position in Q1 2026.
  • Abivax made up ﹤0.01% of Pinnacle Associates's portfolio in Q1 2026, its #903 holding.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.